Skip to content
Clinical Trials – home

Cabotegravir: A Comprehensive Guide for Patients

2 / 9
trials open to patients / all trials
9+
Countries

In short

Cabotegravir is an investigational drug being studied for both HIV prevention and treatment. Clinical trials are evaluating its effectiveness and safety when given as long-acting injections or oral tablets. This article summarizes key findings from recent cabotegravir clinical trials, including its potential as a pre-exposure prophylaxis (PrEP) option and treatment for people living with HIV.

At a glance

Formulations
Long-acting injectable, oral tablets
Dosing frequency
Injectable: Every 8 weeks after initial doses; Oral: Daily
Key trials
HPTN 083, HPTN 084, CAPRISA 014
Efficacy for prevention
Superior to daily oral PrEP in clinical trials
Safety profile
Generally well-tolerated; injection site reactions common
Populations studied
MSM, transgender women, cisgender women
Implementation challenges
HIV testing strategies, adherence to injection schedule
Regulatory status
FDA approved for prevention; approvals pending in other countries

What is Cabotegravir?

Cabotegravir is a medication used in the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. It's also known by its brand name Apretude and the abbreviations CAB or GSK1265744. HIV is a virus that attacks the body's immune system, making it difficult to fight off infections and diseases.

How Cabotegravir Works

Cabotegravir belongs to a class of drugs called integrase strand-transfer inhibitors (INSTIs). These drugs work by blocking an enzyme called integrase, which the HIV virus needs to multiply in your body. By stopping the virus from reproducing, cabotegravir helps to lower the amount of HIV in your blood and prevent it from damaging your immune system.

Uses of Cabotegravir

Cabotegravir is used for two main purposes:

  1. HIV Treatment: It's used as part of a combination therapy to treat HIV infection in adults.
  2. HIV Prevention (PrEP): It's also used as a pre-exposure prophylaxis (PrEP) to prevent HIV infection in adults and adolescents who are at risk of getting HIV through sex.

Forms and Administration

Cabotegravir comes in two main forms:

  1. Oral tablets: These are usually used for a short period before starting the injectable form. They come in 30mg strength and are taken once daily.
  2. Long-acting injectable: This is the main form used for both treatment and prevention. It's given as an injection into the muscle of your buttocks by a healthcare professional. For HIV prevention, it's typically given once every two months after initial doses.

Effectiveness

Clinical trials have shown cabotegravir to be highly effective:

  • For HIV treatment, when used in combination with other antiretroviral drugs, it can significantly reduce the amount of HIV in the blood (viral load).
  • For HIV prevention, studies have shown it to be more effective than daily oral PrEP pills. In one large study, it reduced the risk of getting HIV by 69% compared to daily oral PrEP.

Safety and Side Effects

Cabotegravir is generally well-tolerated, but like all medications, it can cause side effects. Common side effects may include:

  • Injection site reactions (pain, swelling, redness)
  • Headache
  • Fever
  • Fatigue
  • Muscle pain
  • Nausea

Serious side effects are rare but can occur. These may include liver problems or allergic reactions. It's important to discuss all potential side effects with your healthcare provider.

Special Considerations

There are some important things to consider when using cabotegravir:

  • HIV Testing: Before starting cabotegravir for prevention, you must be tested to ensure you don't already have HIV.
  • Adherence: For the injectable form, it's crucial to stick to the scheduled injection appointments to maintain protection against HIV.
  • Drug Interactions: Cabotegravir may interact with other medications. Always inform your healthcare provider about all medicines you're taking.
  • Pregnancy: If you're pregnant or planning to become pregnant, discuss this with your doctor before using cabotegravir.

Ongoing Research

Research on cabotegravir is ongoing to further understand its long-term effects and optimal use. Current studies are looking at:

  • Its use in different populations, including young adults and transgender individuals.
  • Different formulations and dosing schedules.
  • Its effectiveness in real-world settings outside of clinical trials.

Cabotegravir represents a significant advance in HIV treatment and prevention. Its long-acting formulation offers a convenient alternative to daily pills, which may improve adherence and effectiveness for some people. However, like all medical decisions, the choice to use cabotegravir should be made in consultation with a healthcare provider, taking into account individual circumstances and preferences.

Questions people often ask

Conditions where Cabotegravir is being studied

Each condition opens its own overview and trial list

Trials with Cabotegravir

Recruiting trials first

See all 9 →
Quick filters
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).